Search alternatives:
significantly affect » significantly affected (Expand Search), significant effect (Expand Search), significant effects (Expand Search)
better decrease » greater decrease (Expand Search), between decreased (Expand Search)
affect decrease » effects decreased (Expand Search), largest decrease (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
Showing 1 - 20 results of 3,914 for search '(( significantly ((better decrease) OR (teer decrease)) ) OR ( significantly affect decrease ))*', query time: 0.36s Refine Results
  1. 1
    Analysis of the significantly different metabolomic features.

    Analysis of the significantly different metabolomic features. by Bhuripit Saraphol (20855573)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  2. 2
    Correlations between significantly different microbiota and metabolites.

    Correlations between significantly different microbiota and metabolites. by Bhuripit Saraphol (20855573)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Box plots showing the taxa that were significantly different between thin and normal cows.

    Box plots showing the taxa that were significantly different between thin and normal cows. by Bhuripit Saraphol (20855573)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Transepithelial resistance of NHBE decreases significantly after PAA exposure.

    Transepithelial resistance of NHBE decreases significantly after PAA exposure. by Ellie S. Burns (21246537)

    Published 2025
    Save to List
    Saved in:
  5. 5
    DataSheet1_The OsGAPC3 mutation significantly affects grain quality traits and improves the nutritional quality of rice.docx

    DataSheet1_The OsGAPC3 mutation significantly affects grain quality traits and improves the nutritional quality of rice.docx by Bo Peng (273834)

    Published 2024
    “…Additionally, the OsGAPC3 mutation significantly decreases the rice-seedling salt tolerance. …”
    Save to List
    Saved in:
  6. 6
    Socio-demographic and medical characteristics of patients with liver cancer.

    Socio-demographic and medical characteristics of patients with liver cancer. by Ayana Ablayeva (22103708)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    Data cleaning and preparation algorithm.

    Data cleaning and preparation algorithm. by Ayana Ablayeva (22103708)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  8. 8
    Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023.

    Crude and age-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  9. 9
    Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023.

    Crude and type-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific.

    Age-adjusted annual percent changes (APC) in incidence (A), mortality (B), and prevalence (C) rates per 100,000 over 2014–2023 for both sexes and sex-specific. by Ayana Ablayeva (22103708)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Association between socio-demographic and medical parameters and all-cause mortality rates of liver cancer between 2014 and 2023.

    Association between socio-demographic and medical parameters and all-cause mortality rates of liver cancer between 2014 and 2023. by Ayana Ablayeva (22103708)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Crude and stage-specific incidence rate of liver cancer per 100,000 over 2014–2023.

    Crude and stage-specific incidence rate of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Crude and age-specific mortality to incidence ratios of liver cancer per 100,000 over 2014–2023.

    Crude and age-specific mortality to incidence ratios of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023.

    Crude and residence-specific incidence rates (A), all-cause mortality rates (B), and prevalence rates (C) of liver cancer per 100,000 over 2014–2023. by Ayana Ablayeva (22103708)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023.

    Age- and sex- specific median yearly incidence (A) and mortality (B) rate of liver cancer per 10⁶ population over 2014–2023. by Ayana Ablayeva (22103708)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Regional and temporal burden of liver cancer in Kazakhstan (2014–2023).

    Regional and temporal burden of liver cancer in Kazakhstan (2014–2023). by Ayana Ablayeva (22103708)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n 

    Weekly aerobic exercise volume over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Weekly resistance training frequency over time for the DHA and placebo groups combined (n 

    Weekly resistance training frequency over time for the DHA and placebo groups combined (n  by Claire M. Douglas (21238238)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups.

    Quality of life scores at baseline (week 0) and end of chemotherapy (week 18) in the DHA and placebo groups. by Claire M. Douglas (21238238)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Participant demographic and clinical characteristics.

    Participant demographic and clinical characteristics. by Claire M. Douglas (21238238)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: